Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: will biotech overcome its slump?; Sanofi on the future of vaccines; J&J’s M&A ambitions; interview with a Korean immuno-oncology challenger; and a setback for the IL-2 approach in oncology.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 22 April 2022, including: will biotech overcome its slump; Sanofi on the future of vaccines; Johnson & Johnson’s M&A ambitions; interview with a Korean immuno-oncology challenger; and a setback for the IL-2 approach in oncology.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline" - Scrip, 21 Apr, 2022.)
(Also see "Sanofi’s Triomphe On Vaccine Plants Of The Future, Regulatory Speed" - Scrip, 21 Apr, 2022.)
(Also see "J&J Continues Signaling Aggressive M&A Approach To Drive Growth" - Scrip, 19 Apr, 2022.)
(Also see "Too Crowded? ImmuneOncia Looks To Niches To Challenge PD-L1 Space" - Scrip, 20 Apr, 2022.)
(Also see "Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames" - Scrip, 15 Apr, 2022.)